With the recent outbreak in Uganda, Mapp was contracted by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services, to develop emergency doses of MBP134 to address this critical medical need.
Currently, there are no FDA-approved medical countermeasures available for SUDV.
KBI is playing an important role in supporting Mapp's efforts by providing expedited product development support including analytical and manufacturing contributions across multiple global sites.
In September 2022, public health authorities in the Republic of Uganda declared an outbreak of Ebola disease caused by SUDV. According to the World Health Organization, there were 142 confirmed cases and 55 deaths as of December 5, 2022.
Currently, there is no cure for Sudan ebolavirus virus disease, which has a fatality rate of around 50%.
While there is no widely available cure, promising therapeutic options such as MBP134 are in development. MBP134 is a two-antibody therapeutic candidate with demonstrated pan-ebolavirus efficacy in non-clinical studies.
Alternative therapeutic approaches are often restricted to a single member of the Ebolavirus genus.
In contrast, MBP134 confers unprecedented protection against antigenically diverse ebolaviruses at a single dosage.
KBI Biopharma, Inc., a JSR Life Sciences company, is a global contract development and manufacturing organization providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies.
With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs.
Recognized for quality manufacturing, KBI helps partners advance drug candidates into the clinic and to the market.
KBI serves its global partners with eight locations in Europe and the USA.
Mapp Biopharmaceutical, Inc. (San Diego, CA) is a privately owned biotech company that develops novel antibody drugs to prevent and treat infectious diseases, focusing on unmet needs in global health and biodefense.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial